Skip to main content
SpringerLink
Log in

Terapia dell’osteogenesi imperfetta

  • Published:
L’Endocrinologo Aims and scope

Riassunto

L’osteogenesi imperfetta comprende un gruppo di patologie ereditarie del collagene di tipo I che si esprime clinicamente con fragilità ossea e fratture ricorrenti. L’unica terapia che abbia dimostrato di essere in grado di ridurre significativamente l’incidenza di nuove fratture sono i bisfosfonati. Il neridronato è l’unico bisfosfonato registrato al momento in Italia per l’osteogenesi imperfetta.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Byers P. Brittle bones-fragile molecules: Disorders of collagen gene structure and expression. Trends Genet 6: 293, 1990.

    Article  CAS  PubMed  Google Scholar 

  2. Wallis G, Sykes B, Byers PH, Matthews CG, Viljoen D, Beioghton P. Osteogenesis imperfecta type III: Mutations in the type I collagen structural genes, COLIA1 and COLIA2, are not necessarily responsible. J Med Genet 30: 192, 1993.

    Article  Google Scholar 

  3. Sillence D, Senn A, Danks D. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16: 101, 1979.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 363: 1377, 2004.

    Article  CAS  PubMed  Google Scholar 

  5. Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga V, Rossini M, Adami S. The volumetric bone density and cortical thickness in adult patients with osteogenesis imperfecta. J Clin Densitom 6: 173, 2003.

    Article  PubMed  Google Scholar 

  6. Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 64: 185, 1999.

    Article  CAS  PubMed  Google Scholar 

  7. Adami S, Kanis JA. Assessment of involutional bone loss: methodological and conceptual problems. J Bone Miner Res 10: 511–517, 1995.

    Article  CAS  PubMed  Google Scholar 

  8. Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, Adami S. Bone turnover markers in patients with osteogenesis imperfecta. Bone 34: 1013, 2004.

    Article  CAS  PubMed  Google Scholar 

  9. Meunier PJ, Boivin G. Bone mineral density reflectsbone mass but also the degree of mineralization of bone. Therapeutic implications. Bone 21, 373, 1997.

    Article  CAS  PubMed  Google Scholar 

  10. Noda H, Onishi H, Saitoh K, Nakajima H. Growth hormone therapy may increase fracture risk in a pubertal patient with osteogenesis imperfecta. J Pediatr Endocrinol Metab 15: 217, 2002.

    Article  PubMed  Google Scholar 

  11. Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM. Positive linear growth and bone responses to growth hormone treatment in children with type III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type 1 procollagen. J Bone Miner Res 18: 237, 2003.

    Article  CAS  PubMed  Google Scholar 

  12. King D, Jarjoura D, McEwen HA, Askew MJ. Growth hormone injections improve bone quality in a mouse model of osteogenesi imperfecta. J Bone Miner Res 20: 987, 2005.

    Article  CAS  PubMed  Google Scholar 

  13. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131: 622-1997.

    Article  CAS  PubMed  Google Scholar 

  14. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 156: 792, 1997.

    Article  CAS  PubMed  Google Scholar 

  15. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87: 64, 1998.

    Article  CAS  PubMed  Google Scholar 

  16. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947, 1998.

    Article  CAS  PubMed  Google Scholar 

  17. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18: 126, 2003.

    Article  CAS  PubMed  Google Scholar 

  18. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20: 758, 2005.

    Article  CAS  PubMed  Google Scholar 

  19. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 1846, 2000.

    CAS  PubMed  Google Scholar 

  20. DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35: 1038, 2004.

    Article  CAS  PubMed  Google Scholar 

  21. Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tato L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149: 174, 2006.

    Article  CAS  PubMed  Google Scholar 

  22. Gatti D, Viapiana O, Lippolis I, Braga V, Prizzi R, Rossini M, Adami S. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res 20: 1323, 2005.

    Article  CAS  PubMed  Google Scholar 

  23. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 91: 511, 2006.

    Article  CAS  PubMed  Google Scholar 

  24. Shapiro JR, McCarthy EF, Rossiter K, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 72: 103, 2003.

    Article  CAS  PubMed  Google Scholar 

  25. Munns CFJ, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 20: 1235, 2005.

    Article  CAS  PubMed  Google Scholar 

  26. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39: 901, 2006.

    Article  CAS  PubMed  Google Scholar 

  27. Land C, Rauch F, Montpetit K, RuckJubis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 148: 456, 2006.

    Article  CAS  PubMed  Google Scholar 

  28. Huang RP, Ambrose CG, Sullivan E, Haynes RJ. Functional significance of bone density measurements in children with osteogenesis imperfecta. J Bone Joint Surg 88: 1324, 2006.

    Article  PubMed  Google Scholar 

  29. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebocontrolled study. Lancet 363: 1427, 2004.

    Article  CAS  PubMed  Google Scholar 

  30. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21: 132, 2006.

    Article  PubMed  Google Scholar 

  31. Chevrel G, Schott A, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21: 300, 2006.

    Article  CAS  PubMed  Google Scholar 

  32. Madenci E, Yilmaz K, Yilmaz M, Coskun Y. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol 12: 53, 2006.

    Article  PubMed  Google Scholar 

  33. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111: 1030, 2003.

    Article  PubMed  Google Scholar 

  34. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88: 986, 2003.

    Article  CAS  PubMed  Google Scholar 

  35. Vallo A, Rodriguez-Leyva F, Rodriguez J. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr 95: 332, 2006.

    Article  PubMed  Google Scholar 

  36. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 91: 511, 2006.

    Article  CAS  PubMed  Google Scholar 

  37. Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91: 1268, 2006.

    Article  CAS  PubMed  Google Scholar 

  38. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189, 2004.

    Article  CAS  PubMed  Google Scholar 

  39. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19: 1259, 2004.

    Article  CAS  PubMed  Google Scholar 

  40. Rauch F, Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med 37: 295, 2005.

    Article  CAS  PubMed  Google Scholar 

  41. Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21: 374, 2006.

    Article  CAS  PubMed  Google Scholar 

  42. Munns CFJ, Rauch F, Zeitlin L, Fassier F, Glorieux FH Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19: 1779, 2004.

    Article  CAS  PubMed  Google Scholar 

  43. Pizones J, Plotkin H, Parra-Garcia JI, Alvarez P, Gutierrez P, Bueno A, Fernandez-Arroyo A. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop 25: 332, 2005.

    PubMed  Google Scholar 

  44. el-Sobky MA, Hanna AA, Basha NE, Tarraf YN, Said MH. Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study. J Pediatr Orthop B 15: 222, 2006.

    Article  PubMed  Google Scholar 

  45. Weber M, Roschger P, Fratzl-Zelman N, Schoberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 39: 616, 2006.

    Article  CAS  PubMed  Google Scholar 

  46. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457, 2003.

    Article  CAS  PubMed  Google Scholar 

  47. Munns C, Rauch F, Ward L, Glorieux F. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19: 1742, 2004.

    Article  PubMed  Google Scholar 

  48. Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91: 2017, 2006.

    Article  CAS  PubMed  Google Scholar 

  49. Illidge T, Hussey M, Godden C. Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol 8: 257, 1996.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Riabilitazione Reumatologica, Coc Valeggio sul Mincio, Università degli Studi di Verona, Via S. Maria Crocefissa di Rosa 1, 37067, Valeggio sul Mincio (VR), Italia

    Ombretta Viapiana, Luca Idolazzi, Davide Gatti, Maurizio Rossini, Elena Fracassi &  Silvano Adami

Authors
  1. Ombretta Viapiana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Idolazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Davide Gatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Rossini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Fracassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Silvano Adami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvano Adami.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Viapiana, O., Idolazzi, L., Gatti, D. et al. Terapia dell’osteogenesi imperfetta. L’Endocrinologo 9, 28–34 (2008). https://doi.org/10.1007/BF03344601

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344601

Search

Navigation